CTOs on the Move


 
Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70% of cervical cancer, 90% of anal cancer and 69% of vulvar cancer. In addition to HPV, Inovio`s optimized plasmid design ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.inovio.com
  • 660 West Germantown Pike Suite 110
    Plymouth Meeting, PA USA 19462
  • Phone: 267.440.4200

Executives

Name Title Contact Details

Funding

Inovio raised $56M on 04/11/2018
Inovio raised $71M on 06/23/2020
Inovio raised $150.5M on 01/20/2021

Similar Companies

Advanced Life Sciences

Advanced Life Sciences is a Woodridge, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diosynth Biotechnology

Diosynth Biotechnology is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.

AES OPTICS

AES OPTICS is a Senatobia, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genmab

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.